Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.
Reported portfolio value by quarter (24 quarters reported)
$1.39B in Q2 2013 → $3.98B now. Hover for any quarter.
As reported for the quarter ended March 31, 2019. Activity is the change in share count since the prior quarter's filing.
| Holding | % of portfolio | Activity | Shares | Value |
|---|---|---|---|---|
| Ionis Pharmaceuticals Inc. | 15.8% | Trimmed 12% | 7,725,000 | $627M |
| Incyte Corp. | 7.8% | Trimmed 4.9% | 3,620,000 | $311M |
| Neurocrine Biosciences Inc. | 7.5% | Added 0.7% | 3,366,786 | $297M |
| Vertex Pharmaceuticals Inc | 6.0% | Trimmed 5.1% | 1,300,000 | $239M |
| Sage Therapeutics, Inc. | 5.5% | Unchanged | 1,375,229 | $219M |
| C Celgene Corp | 5.2% | Trimmed 4.5% | 2,200,000 | $208M |
| Agios Pharmaceuticals, Inc. | 5.0% | Added 3.5% | 2,978,134 | $201M |
| AP Alexion Pharmaceuticals, Inc. | 4.5% | Unchanged | 1,314,428 | $178M |
| Alnylam Pharmaceuticals, Inc. | 3.8% | Added 3.8% | 1,631,089 | $152M |
| Esperion Therapeutics, Inc. | 3.6% | Added 3.8% | 3,522,964 | $141M |
| RH Radius Health, Inc. | 3.4% | Added 1.1% | 6,781,685 | $135M |
| Halozyme Therapeutics Inc. | 3.4% | Unchanged | 8,322,860 | $134M |
| Argenx Se | 2.8% | Added 2.3% | 904,739 | $113M |
| Moderna, Inc. | 2.4% | Unchanged | 4,785,681 | $97.4M |
| MS Myovant Sciences Ltd. | 2.2% | Unchanged | 3,597,882 | $85.9M |
| Intercept Pharmaceuticals, Inc. | 2.0% | Added 21% | 696,976 | $78M |
| Gilead Sciences Inc. | 1.9% | Trimmed 14% | 1,142,204 | $74.3M |
| Nektar Therapeutics | 1.7% | Added 46% | 2,020,676 | $67.9M |
| Exelixis, Inc. | 1.7% | Unchanged | 2,835,000 | $67.5M |
| AT Akcea Therapeutics, Inc. | 1.7% | Trimmed 0.4% | 2,377,638 | $67.4M |
| M Myokardia Inc. | 1.7% | Added 44% | 1,264,913 | $65.8M |
| Macrogenics Inc. | 1.5% | Added 3.6% | 3,400,000 | $61.1M |
| Wave Life Sciences Ltd. | 1.4% | Unchanged | 1,465,002 | $56.9M |
| Voyager Therapeutics, Inc. | 1.4% | Unchanged | 2,865,841 | $54.9M |
| AT Audentes Therapeutics, Inc. | 1.3% | Added 78% | 1,369,604 | $53.4M |
| AB Alder Biopharmaceuticals Inc. | 0.9% | Unchanged | 2,766,008 | $37.8M |
| Crispr Therapeutics Ag | 0.7% | New | 810,462 | $29M |
| Scholar Rock Holding Corp | 0.7% | Added 15% | 1,476,839 | $27.8M |
| IT Intra-cellular Therapies, Inc. | 0.7% | Unchanged | 2,200,000 | $26.8M |
| Sangamo Therapeutics, Inc | 0.6% | Added 96% | 2,650,000 | $25.3M |
| Kezar Life Sciences, Inc. | 0.5% | Added 49% | 1,220,503 | $21.7M |
| G1 Therapeutics, Inc. | 0.3% | Unchanged | 671,925 | $11.2M |
| Cidara Therapeutics, Inc. | 0.2% | Unchanged | 2,295,272 | $6.08M |
| Novavax Inc. | 0.1% | Unchanged | 8,330,000 | $4.59M |
| HM Homology Medicines, Inc. | 0.1% | New | 91,336 | $2.53M |
What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.
quarter ended March 31, 2019 · filed May 13, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Ionis Pharmaceuticals Inc. | Trimmed | −1,016,334 | −$82.5M | 15.8% |
| Crispr Therapeutics Ag | New | +810,462 | +$29M | 0.7% |
| Regeneron Pharmaceuticals Inc. | Exited | −68,156 | −$25.5M | — |
| AT Audentes Therapeutics, Inc. | Added | +600,200 | +$23.4M | 1.3% |
| Nektar Therapeutics | Added | +639,701 | +$21.5M | 1.7% |
| M Myokardia Inc. | Added | +387,647 | +$20.2M | 1.7% |
| Incyte Corp. | Trimmed | −188,322 | −$16.2M | 7.8% |
| Intercept Pharmaceuticals, Inc. | Added | +121,257 | +$13.6M | 2.0% |
| Vertex Pharmaceuticals Inc | Trimmed | −70,445 | −$13M | 6.0% |
| Sangamo Therapeutics, Inc | Added | +1,300,000 | +$12.4M | 0.6% |
Showing the 10 largest of 23 changes.
quarter ended December 31, 2018 · filed February 12, 2019
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| T Tesaro Inc. | Exited | −2,931,802 | −$114M | — |
| Moderna, Inc. | New | +4,785,681 | +$73.1M | 2.3% |
| Regeneron Pharmaceuticals Inc. | Trimmed | −131,844 | −$49.2M | 0.8% |
| C Celgene Corp | Trimmed | −680,423 | −$43.6M | 4.7% |
| Gilead Sciences Inc. | Trimmed | −622,392 | −$38.9M | 2.7% |
| Agios Pharmaceuticals Inc. | Added | +680,203 | +$31.4M | 4.3% |
| Sage Therapeutics, Inc. | Added | +303,856 | +$29.1M | 4.2% |
| Scholar Rock Holding Corp | Added | +1,090,021 | +$25M | 0.9% |
| Kezar Life Sciences, Inc. | New | +818,432 | +$19.3M | 0.6% |
| M Myokardia Inc. | Added | +367,266 | +$17.9M | 1.4% |
Showing the 10 largest of 29 changes.
quarter ended September 30, 2018 · filed November 09, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Gilead Sciences Inc. | Trimmed | −420,000 | −$32.4M | 4.0% |
| Exelixis Inc. | Added | +1,725,000 | +$30.6M | 1.3% |
| C Celgene Corp | Trimmed | −340,000 | −$30.4M | 7.1% |
| Regeneron Pharmaceuticals Inc. | Trimmed | −70,000 | −$28.3M | 2.1% |
| Argenx Se | Added | +285,690 | +$21.7M | 1.5% |
| Alnylam Pharmaceuticals, Inc. | Added | +230,000 | +$20.1M | 3.2% |
| T Tesaro Inc. | Added | +505,000 | +$19.7M | 3.0% |
| Neurocrine Biosciences Inc. | Trimmed | −159,663 | −$19.6M | 10.3% |
| Nektar Therapeutics | Added | +320,000 | +$19.5M | 1.4% |
| FP Five Prime Therapeutics Inc. | Exited | −977,500 | −$15.5M | — |
Showing the 10 largest of 23 changes.
quarter ended June 30, 2018 · filed August 09, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| A Avexis, Inc. | Exited | −402,800 | −$49.8M | — |
| T Tesaro Inc. | Added | +797,059 | +$35.4M | 3.1% |
| Esperion Therapeutics Inc. | Added | +770,000 | +$30.2M | 3.6% |
| Agios Pharmaceuticals Inc. | Trimmed | −337,322 | −$28.4M | 5.3% |
| Nektar Therapeutics | New | +525,000 | +$25.6M | 0.7% |
| M Myokardia Inc. | New | +480,000 | +$23.8M | 0.7% |
| Exelixis Inc. | New | +1,060,000 | +$22.8M | 0.7% |
| Gilead Sciences Inc. | Trimmed | −300,000 | −$21.3M | 4.9% |
| G1 Therapeutics Inc. | New | +352,607 | +$15.3M | 0.4% |
| Prothena Corp. PLC | Exited | −400,000 | −$14.7M | — |
Showing the 10 largest of 25 changes.
quarter ended March 31, 2018 · filed May 08, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| JT Juno Therapeutics Inc. | Exited | −1,925,000 | −$88M | — |
| T Tesaro Inc. | Added | +583,550 | +$33.3M | 2.6% |
| Argenx Se | New | +396,819 | +$31.9M | 0.9% |
| AT Akcea Therapeutics, Inc. | Added | +1,140,921 | +$29.2M | 1.7% |
| Regeneron Pharmaceuticals Inc. | Added | +75,000 | +$25.8M | 2.7% |
| Ionis Pharmaceuticals Inc. | Added | +380,000 | +$16.8M | 10.4% |
| Agios Pharmaceuticals Inc. | Trimmed | −184,745 | −$15.1M | 5.7% |
| C Celgene Corp | Trimmed | −100,000 | −$8.92M | 8.2% |
| Voyager Therapeutics Inc. | Added | +453,121 | +$8.51M | 1.0% |
| Gilead Sciences Inc. | Trimmed | −100,000 | −$7.54M | 5.6% |
Showing the 10 largest of 20 changes.
quarter ended December 31, 2017 · filed February 14, 2018
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Wave Life Sciences Ltd. | New | +856,096 | +$30M | 0.8% |
| Voyager Therapeutics Inc. | New | +1,539,520 | +$25.6M | 0.7% |
| C Celgene Corp | Added | +240,000 | +$25M | 10.1% |
| AT Akcea Therapeutics, Inc. | New | +1,248,650 | +$21.7M | 0.6% |
| Esperion Therapeutics Inc. | Added | +265,000 | +$17.4M | 4.4% |
| Ionis Pharmaceuticals Inc. | Added | +274,400 | +$13.8M | 11.5% |
| Sage Therapeutics Inc. | Trimmed | −50,000 | −$8.24M | 4.8% |
| Alnylam Pharmaceuticals Inc. | Trimmed | −60,000 | −$7.62M | 3.8% |
| Cidara Therapeutics Inc. | Added | +960,000 | +$6.53M | 0.4% |
| RH Radius Health Inc. | Added | +200,000 | +$6.35M | 5.1% |
Showing the 10 largest of 19 changes.
quarter ended September 30, 2017 · filed November 13, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| KP Kite Pharma Inc. | Exited | −640,000 | −$66.3M | — |
| Esperion Therapeutics Inc. | Added | +584,422 | +$29.3M | 2.9% |
| Ionis Pharmaceuticals Inc. | Added | +507,839 | +$25.7M | 11.0% |
| Incyte Corp. | Added | +153,500 | +$17.9M | 11.9% |
| RH Radius Health Inc. | Added | +460,000 | +$17.7M | 5.9% |
| T Tesaro Inc. | Added | +118,203 | +$15.3M | 3.6% |
| Intercept Pharmaceuticals Inc. | Added | +230,000 | +$13.3M | 0.8% |
| Alnylam Pharmaceuticals Inc. | Trimmed | −110,000 | −$12.9M | 3.6% |
| Sage Therapeutics Inc. | Added | +185,000 | +$11.5M | 1.9% |
| Regeneron Pharmaceuticals Inc. | Added | +25,000 | +$11.2M | 2.5% |
Showing the 10 largest of 20 changes.
quarter ended June 30, 2017 · filed August 11, 2017
| Company | Action | Shares changed | Value of change | % of portfolio |
|---|---|---|---|---|
| Regeneron Pharmaceuticals Inc. | Trimmed | −65,000 | −$31.9M | 2.7% |
| RH Radius Health Inc. | Added | +498,400 | +$22.5M | 7.0% |
| AP Alexion Pharmaceuticals Inc. | Added | +125,000 | +$15.2M | 5.0% |
| C Celgene Corp | Trimmed | −90,000 | −$11.7M | 12.9% |
| Neurocrine Biosciences Inc. | Added | +245,000 | +$11.3M | 4.8% |
| KP Kite Pharma Inc. | Trimmed | −100,000 | −$10.4M | 2.0% |
| Puma Biotechnology Inc. | Exited | −245,616 | −$9.14M | — |
| T Tesaro Inc. | Added | +53,408 | +$7.47M | 3.8% |
| Ptc Therapeutics Inc. | Exited | −682,912 | −$6.72M | — |
| Halozyme Therapeutics Inc. | Added | +515,472 | +$6.61M | 3.2% |
Showing the 10 largest of 24 changes.
Loading...
